Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred W Sandrock

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Annals of Neurology|March 29, 2002
Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analysesRoy W Beck, Danielle L Chandler, Stephen R Cole, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Neuromuscular Disorders : NMD|November 10, 2019
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyDarryl C De Vivo, Enrico Bertini, Kathryn J Swoboda, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Annals of Neurology|March 29, 2002
Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analysesRoy W Beck, Danielle L Chandler, Stephen R Cole, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Neuromuscular Disorders : NMD|November 10, 2019
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyDarryl C De Vivo, Enrico Bertini, Kathryn J Swoboda, et al.
Pageof 2